Developing first in class solutions for unmet health and personal care needs

NovaBiotics publishes further data on the mechanism of action of its candidate NM001 therapy for cystic fibrosis (CF)

Sep 23, 2021

This new data further supports the potential of NM001 against the most clinically challenging bacterial pathogens, including Pseudomonas aeruginosa, in respiratory disease. NM001 is a registration study-ready candidate intervention (acute use) for pulmonary...

« Older Entries

Next Entries »

NovaBiotics provides a positive clinical data update for its breakthrough toenail health product, Tinexyl® PRO

Tinexyl® PRO, marketed by NovaBiotics Consumer Health Ltd and developed by the biotechnology company NovaBiotics, is a first-of-its-kind conditioning product for toenails, only available through UK podiatrists and foot health practitioners. Its unique, proprietary...

NovaBiotics & Liverpool School of Tropical Medicine Collaborate on Cysteamine Bitartrate as a Potential New Intervention in Mycobacterial Disease.

On world TB Day 2025, NovaBiotics Ltd (NovaBiotics) and Liverpool School of Tropical Medicine (LSTM) announce that they are working together to investigate the use of oral cysteamine bitartrate in the treatment of mycobacterial disease, including tuberculosis (TB)....

The Institute of Podiatrists announce endorsement of Tinexyl PRO

The Institute of Podiatrists are delighted to announce their endorsement of Tinexyl PRO. Our Medicines and Procedures Panel (MaPP) were invited to assist with the product review of Tinexyl PRO over a year ago. During this time MaPP have played an active role in...

NovaBiotics Pharma Division Highlighted in Healthcare UK report

The company and its Research & Development activities to tackle antimicrobial resistance, infectious and respiratory disease was highlighted in a recent report by Healthcare UK, a joint initiative of the Department of Health and Social Care, NHS England and the...

NovaBiotics announces move to ONE BioHub

Innovative biotechnology group company NovaBiotics has confirmed that NovaBiotics and NovaBiotics Consumer Health will move into ONE BioHub in Aberdeen. Full details are available here ONE News

NovaBiotics Consumer Health Signs Global Sales and Distribution Agreement for its Breakthrough Nail Health Solution, Tinexyl®.

NovaBiotics Consumer Health Limited (“NCH”), a division of NovaBiotics Limited (“NovaBiotics” or “the Company”), today announced that it has entered into a distribution agreement with Brand Creations Limited (“BCL, for the rights to commercialise and distribute...

TinexylPRO Launched at Key Industry Events

The Institute of Podiatrists (IOP) successfully launched our next-generation personal care nail health system on their stand at the Primary Care Show, May 15th-16th. The IOP will also showcase this highly innovative product at FootHealth 2024, June 3rd-4th. These...

Appointment of Dr Trevor Phillips to the Board of NovaBiotics

ABERDEEN 6 SEPTEMBER 2023. NovaBiotics, the clinical-stage biotechnology company announces the appointment of Dr Trevor Phillips to its board as Non-Executive Director. Trevor is a biotechnology leader who previously held board and C-level roles in pharma and Biotech...

Publication of NovaBiotics’ peer reviewed research on cysteamine’s antiviral and anti-inflammatory mechanisms

Publication of NovaBiotics’ research on the host-mediated anti-viral (including against coronaviruses and influenza) and anti-inflammatory mechanism of action of cysteamine, the active component of its advanced clinical stage NM001 and NM002 product candidates for...

Additional International Organization for Standardisation (ISO) accreditations for NovaBiotics

NovaBiotics adds ISO 14001: 2015 and ISO 45001: 2018 accreditations to its integrated quality management system. ISO 14001: 2015 Environmental Management Systems and ISO 45001:2018 Occupational Health & Safety Systems accreditation have now been awarded to...